Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPAHCT-FUL: AV-101 Long-Term Extension in PAH
NCT05557942Phase 3Terminated
- Sponsor
- Aerovate Therapeutics
- Start
- Nov 2022
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of imatinib in pulmonary arterial hypertension (PAH), sponsored by Aerovate Therapeutics. Started Nov 2022; status: terminated.
02
Drugs
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on NCT05557942.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05557942.